Biosignature Detection for Disease Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective predictive tools for identifying patients at risk of severe disease episodes, such as coronary artery disease and COVID-19, necessitating a non-invasive and accurate means to detect predisposition or risk.
Innovation Solution
Detection of a biosignature comprising hepatocyte growth factor (HGF) and Spondin-1 (SPON-1) in blood samples to identify patients predisposed to or at risk of severe disease episodes, allowing for early medical intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current predictive methods are used, then patient care management remains challenging, but invasive methods are more accurate yet less appealing to patients
Solution Approach 1:
The patent replaces invasive mechanical procedures with a biochemical detection system that measures biomarker levels (HGF, SPON-1, and others) in blood samples. This substitution maintains high diagnostic accuracy while eliminating the discomfort and risks associated with invasive methods, thereby improving patient appeal without sacrificing reliability
Solution Approach 2:
The patent introduces biomarkers as intermediary substances that mediate between the disease state and the diagnostic measurement. These biomarkers serve as reliable indicators of disease risk and can be measured through minimally invasive blood tests, bridging the gap between accurate diagnosis and patient comfort
2Measurement precision
If current predictive methods are used, then individual disease risk cannot be accurately predicted, but complex diagnostic systems are more accurate yet more complicated
Solution Approach 1:
The patent segments the complex diagnostic problem into the measurement of specific, identifiable biomarkers (HGF, SPON-1, and others). Rather than attempting to measure all possible disease indicators, the invention focuses on a segmented set of key biomarkers that collectively provide accurate risk prediction, thereby simplifying the diagnostic system while maintaining precision
Solution Approach 2:
The patent changes the measurement parameters from complex, multi-factorial assessments to specific biomarker concentration levels. By measuring the presence and levels of particular biomarkers in blood samples, the system achieves precise risk prediction through simplified parameter measurement, reducing diagnostic complexity while maintaining or improving accuracy
3Ease of operation
If minimally invasive methods are used, then patient appeal increases, but predictive capability is currently lacking
Solution Approach 1:
The patent introduces biomarkers as intermediary substances that mediate between the disease state and the diagnostic measurement. These biomarkers serve as reliable indicators of disease risk and can be measured through minimally invasive blood tests, bridging the gap between accurate diagnosis and patient comfort
Data Source
AI summary
Disclosed herein are methods and uses for identifying if a patient is predisposed to experiencing a severe episode of a disease and/or at risk of experiencing a severe episode of a disease, comprising detecting the presence of a biosignature comprising biomarkers as described herein. Also disclosed are methods of selecting medical interventions, evaluating the effectiveness of medical interventions, and of preventing and/or treating a severe episode of a disease, comprising detecting the presence of a biosignature comprising biomarkers as described herein and identifying if a patient is predisposed to experiencing a severe episode of a disease and/or at risk of experiencing a severe episode of a disease. Also disclosed are kits for identifying if a patient is predisposed to experiencing a severe episode of a disease and/or at risk of experiencing a severe episode of a disease, comprising a means for detecting the presence of a biosignature comprising biomarkers as described herein.